Promotion: Investments in small cap shares involves a high degree of risk and are not suitable for all investors. Companies listed on the AIM or Aquis market can be highly volatile and are considered high-risk speculative investments.
THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN MEDPAL PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to announce that its wholly owned subsidiary, MedPal Limited, has received formal approval from Norfolk and Waveney Integrated Care Board ("ICB") for the change of ownership of the NHS Pharmacy Contract previously held by Universal Pharmacy Limited (in administration) ("Universal"). This formally completes the acquisition of the assets from Universal as announced by the Company on 1 October 2025 - Link.
The Company is also pleased to provide an operational update for the period since its admission to trading on AIM on 26 August 2025.
NHS Contract Approval
On 4 November 2025, Norfolk and Waveney ICB approved the change of ownership application, marking the official transfer of Universal's NHS Distance Selling Pharmacy ("DSP") contract to MedPal Limited. This represents MedPal AI's first NHS contract and enables MedPal Limited to provide regulated NHS pharmaceutical services nationwide. The General Pharmaceutical Council ("GPhC") ceased issuing new DSP licences in June 2025, making this acquisition particularly significant.
Operational Update
MedPal AI app
The Company continues to develop its AI-driven wellness app, which aggregates data from over 100 wearables and health apps to provide personalised lifestyle guidance. The launch of MedPal.clinic completes the Company's dual-engine business model, creating a highly complementary flywheel that drives demand generation through the wellness app whilst fulfilling clinical needs through MedPal.clinic's regulated pharmacy services. This integrated approach combines AI-driven wellness insights with seamless access to prescription medications, positioning the Company uniquely in the digital healthcare market.
MedPal.clinic
Since the Company's announcement of the Acquisition on 1 October 2025, Medpal Limited dispensed 14,757 prescriptions, each written at least at the current NHS prescription charge of £9.90 per item. This strong initial performance demonstrates significant early demand for the Company's automated pharmacy services and validates its investment in advanced robotic dispensing technology.
The Company has also already received orders for weight loss drugs through its newly launched weight loss service at MedPal.clinic, which was announced on 7 November 2025. This early uptake is beyond the Board's expectations and reflects growing consumer demand for accessible telehealth services combined with rapid medication fulfilment.
Jason Drummond, Chief Executive Officer of MedPal AI, commented:
"We are delighted to announce the formal approval of our NHS contract from Norfolk and Waveney ICB. This milestone marks MedPal Limited's official entry into NHS pharmaceutical services and represents a significant validation of our operational capabilities.
"The strong trading performance since opening our distribution centre has exceeded our initial expectations, with nearly 15,000 prescription items dispensed in the 10 days of operation. This early momentum, combined with encouraging uptake of our private weight loss service, demonstrates the market appetite for our AI-enhanced, automated pharmacy model.
"We remain focused on scaling our operations efficiently whilst maintaining the highest standards of patient safety and service quality. The combination of our NHS contract, state-of-the-art automated dispensing capabilities, and growing private telehealth services positions us well for sustainable growth in the rapidly evolving digital healthcare market.
"The traditional pharmacy model is failing many users on cost, convenience, and accessibility. MedPal AI has built an integrated, AI-powered healthcare ecosystem that operates 24/7, making healthcare easily accessible and more affordable for everyone."
Listen to CEO Jason Drummond discuss the formal approval via the following link: https://www.voxmarkets.co.uk/articles/q-a-with-medpal-ai-ceo-jason-drummond-d9d2880
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company take responsibility for the contents of this announcement.
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP
Louise O'Driscoll/Jo Turner
+44 (0) 20 7213 0880
Clear Capital Markets Limited
Bob Roberts/ Nick Josh
+44 (0) 20 3869 6080
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
Fill out the short form below to get instant access to this free report revealing our Top 10 stock picks for November.
Nothing in the above article should be considered investment advice.
Small Cap or Aquis listed companies can be highly illiquid making them difficult to sell at the quoted price, and in some cases, it may be difficult to sell them at any price. Small Cap or Aquis listed companies can have a large bid / offer spread which means there could be a large difference between the buying and selling price. Companies listed on the Aquis market can be highly volatile and are considered high risk speculative investments. The value of your investment can go down as well as up, your Capital is at risk you may not get back the amount invested. Please ensure that you fully understand the risks involved. If in any doubt, please seek independent financial advice. This document is published by Clear Capital Markets and does not constitute a solicitation or personal recommendation for the purchase or sale of investment. The investments referred to may not be suitable for all investors. Any data or views given should not be construed as investment advice. Every effort is made to ensure the accuracy of the information, but no assurance or warranties are given.
Clear Capital Markets Corporate Broking acts as a Corporate Broker to MedPal PLC and holds warrants and shares in the company. Employees and/or directors of Clear Capital Markets may deal in shares of MedPal PLC for their own personal accounts. These scenarios may give rise to a conflict of interest where Clear Capital Markets also provides clients with an advisory service for transactions involving MedPal PLC. The firm has established Conflicts of Interest (“COI”) and Personal Account Dealing (“PAD”) policies to mitigate the risk of a conflict causing damage to the interests of its clients. The measures taken include (i) enforcing minimum holding or ‘lock-in’ periods; and (ii) requiring internal review and approval from the compliance department for employees or directors entering into personal transactions involving MedPal PLC. The COI and PAD policies are available upon request. Before Clear Capital Markets proceeds with a placing, a number of factors are considered including: liquidity of stock, company diversification, market capitalisation and potential news flow. Only once minimum criteria are satisfied would we elect to proceed. Any remuneration payable to Clear Capital Markets has no bearing on whether it proceeds with a placing. These administrative controls mitigate the risk of a conflict causing damage to the interest of a client, but the inherent risks of this business model cannot be eliminated. Accordingly, Clear Capital Markets is required to disclose this conflict to help clients to assess the service that they are being offered in light of Clear Capital’s own interests, and to decide on the extent (if at all) to which they will rely on, or proceed with, the service.
We will reach out for a quick introductory fact find to see how we can best serve your specific needs and arrange a convenient time for a consultation with a member of the appropriate specialist team.
An Advisory Broker will contact you for a deeper fact find and share information on how we can best enhance your portfolio.
We will conduct a full RCP in accordance with FCA regulations to ensure that your appropriate risk profile is set. You will then have access to an extensive suite of investments, supported by your dedicated Advisory Broker.
